Subscribe to gain insight and stay ahead of emerging trends

Subscribe at cas.org/insights



Articles Ш



Topics:

Drug Discovery **Sustainability**

Emerging Science Intellectual Property

Consumer Goods Synthetic Chemistry Digital R&D Safety Biotechnology **Materials**







linkedin.com/company/cas

@CASchemistry



EMERGING TRENDS TO WATCH IN 2024: WEBINAR

From novel therapies, AI, materials, energy, & more...

© 2024 American Chemical Society. All rights reserved.



A division of the American Chemical Society

CAS connects the world's science

At CAS, our passion is advancing scientific progress.

We are proud to partner with innovators across industries, enabling them to maximize the power of connected scientific information to advance discovery and get solutions to market faster.







CAS connects you to the world's published science for better insights



Over **50K** scientific journals and documents Over **250** million substances

50 languages translated

109 patent offices worldwide



Introductions



Dr. Jonathan Allen

Informaticist team lead for small molecule drug discovery with AI/ ML at Lawrence Livermore National Laboratory



Dr. Arnold Lumsdaine

Director of Innovation (INFUSE) Oak Ridge National Lab



Dr. Yiying Wu

Professor of Chemistry specializing in energy storage and batteries **The Ohio State University**



Janet Sasso

Information Scientist specializing in life sciences and biotechnology **CAS**



Dr. Kevin Hughes

Information scientist specializing in materials science and applied physics **CAS**



Dr. Angela Zhou

Manager scientific insight and analysis

Moderator

CAS



TACKLING THE UNDRUGGABLES

Advancements and Emerging Trends

Janet Sasso, Information Scientist, CAS

© 2024 American Chemical Society. All rights reserved.






127 mari


CODE 10 NO

Anti-amyloid agents






Anti-amyloid agents






Anti-amyloid agents






Anti-amyloid agents





Parkinson's disease and biomarker validation

Alpha-Synuclein







¹² © 2024 American Chemical Society. All rights reserved.

Created with BioRender.com

Parkinson's disease and biomarker validation

Alpha-Synuclein






Created with BioRender.com

A division of the American Chemical Society

Antibody-drug conjugate (ADC)


Targeted Immunotherapeutic





ADC Publication Trends

50x increase in patent publications since 1990s



Global patent trend for ADCs from 1990 to 2022 (CAS Content Collection[™])

15 © 2024 American Chemical Society. All rights reserved.


Trends

- Despite a pandemic, explosive growth of publications since first FDA approved ADC in 2000
- Nearly 30% increase in patents alone from 2020 onward



Oncology is leading the clinical pipeline

Expanding efforts to fill gaps left by conventional drugs



Trends

- Breast cancer and autoimmune disease lead paper publications
- Latest FDA ADC approvals target ovarian, head and neck, cervical, and gastric cancers.
- Outside of oncology, ADCs in clinical trials are exploring the treatment of autoimmune disorders and amyloidosis



Gain insights on emerging 2024 trends and more



Janet Sasso Information Scientist jsasso@cas.org

CAS Insights article cas.org/trends

Executive Summaries

E Insight Reports

Journal Publications

Subscribe to stay connected and follow us on:



facebook.com/CAS



linkedin.com/company/cas

X @CASchemistry



AI/ML developments in drug discovery

Jonathan Allen, Ph.D. Informatics Scientist allen99@llnl.gov


January 25, 2024




LLNL-PRES-859442 This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344. Lawrence Livermore National Security, LLC




Adding AI/ML decision making to drug discovery



Improved active learning workflows



Recent example of automated iterative chemical synthesis



Koscher et al., 2023: https://www.science.org/doi/10.1126/science.adi1407



Limited examples of clinical success with signs of potential

- A handful of examples of Investigational New Drug (IND) filings with early clinical trials

 These are small molecules
- More examples of de novo drug design showing on target potency and promising pharmacokinetic/safety profiles
 - Likely still challenges with modeling complexity in human biology
 - Potential improvements with better omics measurements to stratify patient population
- Antibody redesign to restore potency is generating impact
 - De novo design still requires further work
- Improvements in protein folding prediction are opening up potential for new de novo biologics design
 - Added potential for peptide design






Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

Traditional chemical search methods do not scale well




Chemical building blocks for compound synthesis

100K+ building blocks ad growing!






Generative molecular models similar to models in other domains





Generative chemical model search larger chemical spaces



Lawrence Livermore National Laboratory

Bian and Xie 2021, JMM





Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

INNOVATION AT THE INTERSECTION OF BIOMEDICINE AND MATERIALS SCIENCE

A quantitative review of emerging trends

Kevin Hughes, Information Scientist, CAS

© 2024 American Chemical Society. All rights reserved.



A division of the American Chemical Society

Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:

Innovation is often found at the intersection of disciplines




Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:

 Innovation is often found at the intersection of disciplines



Choi, Y. S., et al. Stretchable, dynamic covalent polymers for soft, long-lived bioresorbable electronic stimulators designed to facilitate neuromuscular regeneration. *Nature Communications* **2020**, *11* (1), 5990




Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:

- Innovation is often found at the intersection of disciplines
- Goal of this analysis: provide <u>data-based support</u> for decision making and R&D planning




Choi, Y. S., et al. Stretchable, dynamic covalent polymers for soft, long-lived bioresorbable electronic stimulators designed to facilitate neuromuscular regeneration. *Nature Communications* **2020**, *11* (1), 5990



Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets

Query CAS Content Collection to select journal and patent publications in biomaterials Natural Language Processing (NLP) to identify concepts








Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets




NLP-identified concepts also scored using:

- Publication rate
- Relative growth rate
- Citations



Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets



Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data



Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

- Programmable biomaterials
- Self healing biomaterials



Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

Compositions

- Programmable biomaterials
- Self healing biomaterials
- Protein based materials
- Lipid based materials



Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

- Programmable biomaterials
- Self healing biomaterials

- Compositions
- Protein based materials
- Lipid based materials


Applications

- Bioinks
- Bioelectronic materials
- Antibiotic materials
- Sustainable alternatives for biomedical materials



Programmable biomaterials

Stimulus type is a key aspect




Azam, A., et al. Self-folding micropatterned polymeric containers. *Biomed Microdevices* **2011**, *13*(1), 51-58



Programmable biomaterials

Stimulus type is a key aspect



Trend Analysis:

- pH and magnetic stimuli appear more prominently in journal publications
- Mechanical and temperature-based stimuli appear relatively more in patents




For more details visit cas.org/biomaterials



Dr. Kevin Hughes Information Scientist khughes@cas.org





Insight Reports

Journal Publications

ries

BIOMATERIALS INNOVATIONS FOR THE

mechanical strength, chemical and therma stability, carbon nanotubes have been use

bioelectronic applications such

in vitro-detection

W MINISTER

nic and mechanical properties is also wide

n biosensor applications. Nanomaterials n advantage over others in the injectable

ic devices owing to their size

00044444444

Subscribe to be the first to know about Phase 2's publication:



facebook.com/CAS



linkedin.com/company/cas







Trends in Battery Energy Storage

Yiying Wu

Department of Chemistry & Biochemistry The Ohio State University Columbus, Ohio







M. Stanley Whittingham* and Jie Xiao

- MRS Bulletin **48**, 1118–1124 (2023).







Cell Chemistry

- Li metal anode.
- Solid-state batteries.
- Sodium and potassium-based batteries.
- Extreme Conditions.
- Sulfur batteries.
- Oxygen batteries

Beyond the Cell Chemistry



- Manufacturing technologies for batteries: reducing energy consumption and transportation costs.
- - Regional supply chains and clean mining with renewable energy.
- From Cradle to Cradle: Recycling for reducing waste and recovering materials from end-of-life batteries.
- Safety is a big concern, and overdesigning safety into materials and systems is necessary.



Nuclear Fusion Energy

Arnold Lumsdaine

Director, Innovation Network for Fusion Energy (INFUSE) Oak Ridge National Lab

January 25, 2024


FUSION ENERGY

010010010

ORNL is managed by UT-Battelle, LLC for the US Department of Energy



The Future of Our Civilization Depends on Energy



 Projected need for ~ 35,000 GW from non-CO₂ producing sources

35,000 1 GW-e plants !!!

- By 2050, annual global energy investment would need to reach \$0.66 T (\$23 T cumulative)
 - GDP (2018): US: \$21T, China: \$14T, UK: \$2.9T
 - Global cell phone market: \$0.55 T

Source: IRENA, Global energy transformation, 2019

Source: IPCC AMPERE Project, AMPERE-450-FullTech-OPT Scenario


A New Era in Fusion Energy Development Has Dawned

Confluence of developments have positioned fusion for a major 20-year push

- Achievements on National Ignition Facility and Joint European Torus demonstrate fusion energy production
- Multiple reports for U.S. expert groups indicate readiness and urgency of fusion development
- Extensive predictive tools for optimizing performance now in place
- New technologies available to address key challenges
 - Superconductors, Materials by Design, Advanced Manufacturing, High Performance Computing
- Significant escalation in investment in clean energy \rightarrow new \$\$\$ to make push possible



BURNING PLASMA





The National Academies says that it's time






TT) NATIONAL ACADEMY OF ENGINEE





NAE (2017)

Identified "Provide energy from fusion" as a grand challenge for the 21st century



NASEM (2018)


"Now is the right time for the United States to develop plans to benefit from its investment in burning plasma research and take steps towards the development of fusion electricity for the nation's future energy needs"

NASEM (2021)

"Successful operation of a pilot plant in the 2035–2040 timeframe requires urgent investments by DOE and private industry both to resolve the remaining technical and scientific issues and to design, construct, and commission a pilot plant."



Private investment in fusion has surged in recent years



Currently over \$6B invested

https://www.fusionindustryassociation.org/news/from-the-fia/#industry-reports

49 **CAK RIDGE** National Laboratory



US government has announced a decadal initiative to develop fusion energy

White House Summit on Developing a Bold Decadal Vision for Commercial Fusion Energy

Fusion is a potential carbon-free, abundant source of clean energy that will bolster American leadership, strengthen energy security, and enable sustained energy independence"



Rep. Chuck Fleischmann (TN) US ITER Project Director Kathy McCarthy speaking during the White House summit on March 17, 2022



Department of Energy Focus on Public-Private Partnerships

INFUSE program


National Laboratory

• Enables private firms to tap into national lab and university resources to address key issues https://infuse.ornl.gov/ - Led by ORNL and PPPL Innovation Network for Fusion Energy **Fusion Industry Association** 11 Participating DOE labs **WI** Otae BROOKHAVEN Commonwealth Fusion Systems **ZAP ENERGY** LAWRENCE LIVERMORE ATIONAL LABORATOR TYPE ONE awrence Berkele (IT HELION ENERGY deneral fusion Stational Laboratory Pacific Northwest A HB11 FOCUSED ENERGY irst light National Laboratories GAUSS EUSION NVALANCHE XCIMER ENERGY CORPORATION · Los Alamos Savannah River National Laboratory 🛟 Fermilab **EX-Fusion** ∧ MarvelFusion **CAK RIDGE**

Milestone Program


- In 2023, the DOE Office of Fusion Energy Sciences launched a milestone-based fusion development program, with \$46M for private companies (with 50% cost share) towards the development of fusion power with completion of preliminary design expected within 5 years.
- Eight awards were announced:
 - Commonwealth Fusion Systems
 - Focused Energy, Inc.
 - Realta Fusion
 - Thea Energy
 - Tokamak Energy
 - Type One Energy
 - Xcimer Energy Corporation
 - Zap Energy

Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges







Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges



Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges




Technical readiness must be advanced rapidly to meet ambitious timelines for fusion implementation






Materials challenges are complex involving multiple extremes




Fusion Facilities in the Next Decade

- **ITER** is a 35-nation collaboration under construction in Cadarache, France, and is expected to produce 500 MW fusion power for 400s, and begin operation in the 2030's.
- The **MPEX** project will the support the development of candidate plasma facing materials and is currently under construction, with operation expected in early 2028.
- A **Fusion Prototypic Neutron Source** has been identified by the fusion community as a critical next facility to fill critical material science gap for exposure to fusion neutrons.




MPEX Target Exchange Chamber (TEC)



Multibeam D⁺ into T gas target

D – Li stripping reaction ~5 MW D accelerator and liquid Li target





Gain insight at the intersection of science, tech and innovation

Connect with us at cas.org/insights







Topics:

Drug Discovery Sustainability Emerging Science Intellectual Property

Consumer Goods Synthetic Chemistry

Digital R&D Safety Biotechnology Materials







linkedin.com/company/cas

X @CASchemistry

